NCT00625378View on ClinicalTrials.gov

Sorafenib Long Term Extension Program

PHASE3CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

December 21, 2007

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions

Neoplasms

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

At the same dose and schedule as in the participants' original clinical trials

Trial Locations (74)

106

Taipei

115

Kiev

736

Tainan City

833

Kaohsiung City

1023

Auckland

1200

Bruxelles - Brussel

2031

Randwick

4002

Plovdiv

6000

Charleroi

9010

Varna

10002

Taipei

10043

Turin

12200

Berlin

19104

Philadelphia

20089

Milan

20122

Milan

20133

Milan

20246

Hamburg

22927

Großhansdorf

27100

Pavia

28040

Madrid

28041

Madrid

33000

Bordeaux

33011

Oviedo

33305

Taoyuan District

40138

Bologna

40447

Taichung

42123

Reggio Emilia

45239

Essen

46014

Valencia

53100

Siena

56126

Pisa

78229

San Antonio

82131

Gauting

90025

Los Angeles

93042

Regensburg

100021

Beijing

200030

Shanghai

310022

Hangzhou

510080

Guangzhou

700721

Daegu

710032

Xi’an

06511-5991

New Haven

01246-903

São Paulo

T2N 4N1

Calgary

T6G 1Z2

Edmonton

M5G 2C4

Toronto

M5G 2M9

Toronto

H3A 1A1

Montreal

H3G 1A4

Montreal

H3T 1E2

Montreal

Unknown

Floridablanca

Hong Kong

06132

Perugia

80-219

Gdansk

61-848

Poznan

70-111

Szczecin

02-781

Warsaw

04-141

Warsaw

50 - 556

Wroclaw

03080

Seoul

03722

Seoul

06351

Seoul

03010

Alicante

08003

Barcelona

08035

Barcelona

08036

Barcelona

SO16 6YD

Southampton

ME16 9QQ

Maidstone

CF14 2TL

Cardiff

SM2 5PT

Sutton

G12 0YN

Glasgow

SE1 9RT

London

SW3 6JJ

London

Sponsors

Lead Sponsor

Collaborators (1)

ICON Clinical Research

All Listed Sponsors

collaborator

ICON Clinical Research

INDUSTRY

lead

Bayer

INDUSTRY